The genomic biomarker market in China is estimated to grow significantly at a CAGR of over 17% during the forecast period. China has emerged as a strong player in the biotechnology sector that results from the huge investments in R&D by the Chinese government. Chinese life science sector has progressively grown in the last years as a result of strong R&D and funding. The Chinese government has invested enormously in the cancer diagnostics making it a prominent region for the biomarker industry. China’s substantial patient populations in urban markets and research capability in genome sequencing have formed substantial opportunities for foreign companies. China has a clear market development priority for the IVD industry in the areas of cancer diagnostics, sequencing-based cancer assays, and companion diagnostics.

Request a Free Sample of our Report on CHINA Genomic Biomarker Market: https://www.omrglobal.com/request-sample/china-genomic-biomarkers-market

The genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. On the basis of end-user, the market is segmented into hospitals and diagnostic.

A full Report of CHINA Genomic Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/china-genomic-biomarkers-market

Some of the major players in the China genomic biomarker market include F. Hoffmann-La Roche Ltd., Pfizer Inc., Thermo Fisher Scientific Inc., Cancer Genetics Inc., BGI Group, and others. These companies are launching innovative products in the market, in order to meet the increasing demand for an effective diagnostic biomarker for cancer and cardiovascular diseases. Furthermore, the market players are adopting various strategies, in order to sustain in the competitive market, which includes partnership and collaboration, and investments. For instance, in March 2019, BGI Group planned to commercialize Natera’s Signatera molecular residual disease (MRD) test in China, and develop reproductive health tests in select markets on BGI's sequencing instruments, through a $50 million partnership announced by the two companies.

Market Segmentation

China Genomic Biomarker Market by Application

• Oncology
• Cardiology
• Neurology
• Others

China Genomic Biomarker Market by End-User

• Hospitals
• Diagnostic & Research Laboratories

Company Profiles

• Becton, Dickson, and Co.
• BGI Group
• Cancer Genetics, Inc.
• Complete Genomics Inc.
• Denovo Biopharma
• Epigenomics AG
• F-Hoffman-La Roche Ltd.
• Ipsos Group
• Novartis AG
• Novogene Corp.
• Pfizer, Inc.
• Thermo Fisher Scientific Inc.

 For More Customized Data, Request for Report Customization @https://www.omrglobal.com/report-customization/malaysia-protective-gloves-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com 
Contact no: +1 646-755-7667, +91 780-304-0404